US Biotechnology: The Biotech Brief: Week of July 3, 2026

Research evidence excerpt

US Biotechnology: The Biotech Brief: Week of July 3, 2026

Upcoming Catalysts:

Exhibit 1: Upcoming catalysts in our coverage universe

A look ahead at key data, decisions, and milestones. See our catalyst tracker for more.

Ticker Date Catalyst

BBIO 7/10/2026 FDA decision on encaleret NDA in ADH1 expected by July 10th

SNDX 7/14/2026 R&D Day highlighting late stage axatilimab programs

BIIB 7/14/2026 Phase 2 CELIA BIIB080 data presentation at AAIC at 9-10:30am EDT

Phase 2 SURF302 NMIBC readout (initial thoughts from our Vegas dinner; our SURF-

TYRA 8/2026

302 preview)

Leqembi IQLIK subcutaneous initiation PDUFA (see our takes on the Leqembi PDUFA

BIIB 8/24/2026

extension)

Phase 3 ACACIA-HCM aficamten in nHCM LBA at ESC at 10:15-10:30am EDT (see our

CYTK 8/29/2026

topline ACACIA takes)

Source: BofA Global Research

BofA GLOBAL RESEARCH

Upcoming/ Ongoing Conferences:

• ONGOING European Society for Medical Oncology Gastrointestinal Cancers

Congress (ESMO GI): July 1-4; Munich

• Cell & Gene Therapy Summit (CGT): July 6-8; Boston

• International Society for Stem Cell Research Annual Meeting (ISSCR): July 8-11;

Montreal

• International Society on Thrombosis and Hemostasis Congress (ISTH): July 11-

15; Paris

• Alzheimer’s Association International Conference (AAIC): July 12-15; London

• American Head & Neck Society International Meeting (AHNS): July 18-22;

Boston

Recent Research:

• Is Alzheimer’s biology the same across all populations? In a meta-analysis of

>17k participants, Hispanic individuals with cognitive impairment or APOE ε4

positivity had lower brain amyloid burden and lower odds of amyloid pathology

compared to non-Hispanic White individuals, raising questions about how

broadly anti-amyloid biomarkers and therapies apply across populations

(Alzheimers Dement, 2026 June).